Pro-life advocates are demanding answers from the White House after the FDA approved a new abortion pill in a “shocking” decision earlier this week.

The FDA on Tuesday gave approval for Evita Solutions to distribute mifepristone, a drug that is used to end the life of an unborn child in up to 63% of all abortions. After a pregnant woman takes mifepristone, her unborn child is cut off from the nutrients it needs to survive and is effectively starved to death. A different drug is then taken to induce labor and expel the deceased baby from the mother. 

The fatal drug has been increasingly available after the Biden administration allowed it to be mailed by doctors. Leftist activists ship the drugs illegally across the country with impunity. 

Senator Josh Hawley (R-MO) called the approval “shocking” and said he had lost faith in FDA leadership. 

“This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child,” Hawley wrote on X. 

“FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution. I have lost confidence in the leadership at FDA,” he added. 

Rep. Mark Harris (R-NC) also questioned the move.

“Wow! The FDA just approved a generic version of the abortion pill, Mifepristone, a drug that ends a baby’s life 100% of the time and harms mothers. The FDA announced a new safety study just days ago, so why this new move now?” he wrote on X.

Only two other drug companies, Danco Labs and Genbiopro, were previously approved to distribute the life-ending drug. The FDA wrote to Evita Solutions on September 30 that it had “concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval.”

Evita Solutions says on its website that “medical abortion care is rife with medically unnecessary restrictions and social stigma in the United States” and that it “believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care, regardless of their race, sex, gender, age, sexuality, income, or where they live.”

In response to questions about the drug’s approval, Health and Human Services Communications Director Andrew Nixon told The Daily Wire that the FDA “has very limited discretion in deciding whether to approve a generic drug. By law, the Secretary of Health and Human Services must approve an application if it demonstrates that the generic drug is identical to the brand-name drug.”

Nixon added that applicants for generic drugs do not need to submit independent evidence proving safety and efficacy. 

“HHS is conducting a study of the reported adverse effects of mifepristone to ensure the FDA’s risk mitigation program for the drug is sufficient to protect women from unstated risks,” Nixon added. “The FDA does not endorse any drug product and directs prescribers to follow all labeling.”

The decision is already drawing backlash from pro-life advocates who have long warned about the dangers of the drug. Kelsey Pritchard, the director of state affairs for SBA Pro-Life America, called the decision “reckless.”

“This does nothing to help and fix the problem that we have with abortion drugs and mail-order abortion drugs, and instead puts a cheap drug on the market so that more unborn lives are taken and more women and girls end up in the ER,” she told The Daily Wire. 

Pritchard said that the Trump administration should reinstate restrictions on the mailing of mifepristone that the Biden administration loosened. 

“This decision is not MAGA. It is not MAHA, adding a new life ending drug to the market doesn’t make America greater or healthier, and this is not something that we would expect, especially at this time,” she added, calling for pro-life Republicans to call out the decision. 

Last month, HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary told Republican attorneys general that they were studying the safety of mifepristone. Some studies have shown that the drug is not only fatal to the unborn child but can also bring serious health risks to the mother.

The CEO of the “wokest insurance company” in America once said that a bill to keep men out of women’s bathrooms was a “threat to democracy,” a watchdog organization revealed.

Chubb Corporation CEO Evan Greenberg attacked North Carolina Republicans over a 2016 bill aimed at protecting women’s privacy, video discovered by Consumers’ Research shows. Operating across 54 countries, Chubb Insurance is the largest commercial lines insurer in the United States.

Greenberg’s comments were highlighted in a “woke alert,” first shared with The Daily Wire, sent out Thursday by the watchdog group to over 100,000 people.

“The rights of individuals, including our personal freedom and right to pursue happiness, are a universal right. We protect them. Actions like those in North Carolina and other states to discriminate against sexual preference and strip citizens of their protections, do not reflect who we are as a nation, and are ultimately, I believe, a threat to democracy,” Greenberg said.

The bill Greenberg was referring to was one that required people to use public bathrooms in accordance with their sex. The intent was to keep transgender-identifying men out of women’s bathrooms. It also prohibited local governments from putting in place so-called non-discrimination laws allowing men into women’s bathrooms.

“After all, where does it stop? This is something we’re speaking about, and that’s why I’m speaking out about it,” Greenberg said.

His comments were made during a speech at the Chubb Leadership Forum, an insurance conference held in San Diego on April 12, 2016.

“Chubb prioritizes pushing a woke agenda to such an extreme extent that it’s earned the title of ‘wokest insurance company,’” Consumers’ Research executive director Will Hild told The Daily Wire. “Chubb should be focused on delivering the best insurance policies for its customers, not carrying water for repulsive ideological causes.”

Consumers’ Research first launched a national campaign highlighting Chubb’s woke policies on Wednesday. The campaign included a national TV ad, mobile billboards outside Chubb offices in Washington, D.C., and New York City, and a letter demanding the Treasury Department launch an investigation into the insurance giant’s DEI practices.

The Chubb Charitable Foundation has previously donated to the radical LGBT organization The Trevor Project, which pushes transgender ideology on kids.

Chubb also has a 95% score from the far-Left Human Rights Campaign, which documents that the corporation “provides four LGBTQ+ internal training elements (including an intersectionality training)” and “provides Gender Transition Guidelines and at least one additional transgender inclusive policy or practice for its employees.”

The insurance company’s website is also full of diversity, equity, and inclusion language and it offers employees resources like a “Race Fluency Toolkit” and a “Race Matters” platform “to facilitate greater consciousness of racism and understanding of the Black experience.”

“We believe in being anti-racist because a rejection of racism alone is insufficient,” the company’s website says, noting that it places an emphasis on hiring employees from “underrepresented groups.”

In fact, in a 2021 interview, a Chubb executive said that “Diversity, equity and inclusion are the foundation of our Chubb culture.”

Chubb has also committed to no longer underwriting “the construction and operation of new coal-fired plants or new risks for companies that generate more than 30% of their revenues from coal mining or energy production from coal.”

Hild said that customers should “be warned that doing business with Chubb is doing business with a company that has no problem fully embracing the most polarizing political agendas.”